12:00 AM
 | 
Nov 16, 2009
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Affitech, Peregrine preclinical data

In a mouse model of breast cancer, r84 inhibited cancer growth at least as well as Avastin bevacizumab and Sutent sunitinib and was superior to both drugs in limiting...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >